Decibel Therapeutics, Inc. (NASDAQ: DBTX)


Engel Law PLLC is investigating whether fair value to Decibel Therapeutics, Inc. (NASDAQ: DBTX) shareholders will result from the proposed acquisition of Decibel by Regeneron Pharmaceuticals, Inc. for (i) $4.00 in cash and (ii) one non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones for each Decibel share.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Decibel Therapeutics, Inc.

MM slash DD slash YYYY